期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 18, 页码 8601-8620出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01050
关键词
-
资金
- National Health and Medical Research Council (NHMRC) Australia [1021607, 1048972]
- NHMRC Senior Principal Research Fellowship [1062607]
- NHMRC RD Wright Career Development Fellowship [1083057]
- Australian Research Council [DP1096029, DP150104672, DP1211465, 10/CDF/2-15]
- Cancer Institute NSW
- National Breast Cancer Foundation
- Australian Research Council [DP1096029] Funding Source: Australian Research Council
- National Breast Cancer Foundation [PS-16-030] Funding Source: researchfish
Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) represents a significant impediment to successful cancer treatment. The compound, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), has been shown to induce greater cytotoxicity against resistant cells than their nonresistant counterparts. Herein, the structure-activity relationships of selected thiosemicarbazones are explored and the novel mechanism underlying their ability to overcome resistance is further elucidated. Only thiosemicarbazones with electron-withdrawing substituents at the imine carbon mediated Pgp-dependent potentiated cytotoxicity, which was reversed by Pgp inhibition. Treatment of resistant cells with these thiosemicarbazones resulted in Pgp-dependent lysosomal membrane permeabilization (LMP) that relied on copper (Cu) chelation, reactive oxygen species generation, and increased relative lipophilicity. Hence, this study is the first to demonstrate the structural requirements of these thiosemicarbazones necessary to overcome MDR. We also demonstrate the mechanism that enables the targeting of resistant tumors, whereby thiosemicarbazones hijack lysosomal Pgp and form redox-active Cu complexes that mediate LMP and potentiate cytotoxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据